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ABSTRACT
BACKGROUND AND OBJECTIVES
The cardiovascular system and the thyroid gland are linked to each other 
at multiple ways and in many ways. Hypothyroidism and hyperthyroidism are 
both associated with an increased risk of coronary artery disease. 
The sick euthyroid state or the low free T3 state is characterised by a 
normal level of TSH, normal free T4 , a reduced free T3 and elevated reverse 
T3.This state is usually seen when the patient suffers from any serious illness.
This study is done to analyse the effects of the sick euthyroid state on the 
outcome of patients admitted with ST elevation Myocardial infarction.
METHODS
75 patients admitted at Government Rajaji Hospital with ST elevation 
Myocardial Infarction in the period between September 2013 and August 2014 
were included in the study. ST elevation myocardial infarction was diagnosed 
with the help of history, clinical examination and a 12-lead ECG.
Thyroid profile was done for all the 75 patients at the time of admission. 
Patients with prior history of any endocrine disorder (excluding diabetes 
mellitus), chronic kidney disease, chronic liver disease, oral contraceptive use, 
malignancy were excluded from the study. The study population was divided 
into 3 groups based on the thyroid profile- those with a normal thyroid profile, 
those with a sick euthyroid state and hypothyroid patients. All 3 groups were 
followed up till discharge or death and the incidence of MACE (major adverse 
cardiac events-cardiac failure, ventricular arrhythmias and death) was studied.
The sick euthyroid group and the normal thyroid profile groups were compared 
in terms of in-hospital short term outcome. 
RESULTS
All the patients were followed up till discharge or death. Out of the 75 
patients included in the study, 52 had a normal thyroid status, 8 were 
hypothyroid and 15 had a sick euthyroid state.
Cardiac failure (66.67%, p<0.0001), ventricular arrhythmias                
(33.33%, p<0.012) and death (75%,  p<0.0002)  were found to occur more 
frequently in the sick euthyroid group.
The incidence of MACE was 80% in the sick euthyroid group (12 out of 
15 patients) with a p value of <0.0001.
INTERPRETATION AND CONCLUSION
Patients with ST elevation Myocardial Infarction who have a sick 
euthyroid state at the time of presentation have a poor prognosis. They have a 
higher incidence of mortality, cardiac failure and ventricular arrhythmias.
KEY WORDS
Sick euthyroid state, ST elevation myocardial infarction, MACE-major adverse 
cardiac events, cardiac failure, prognosis
1INTRODUCTION
                   Coronary artery disease is one of the leading causes of 
mortality in the world today-contributing to almost 13% of all the deaths 
annually. It is the most common cause of mortality in the non-
communicable disease category. In India, cardiovascular disease 
accounted for 26% of all deaths in 2008. The proportion of Indians who 
develop CAD during their productive years is more when compared to 
the western countries.This is because CAD  occurs at an earlier age in 
Indians. Over the last 30 years, the prevalence of CAD in India has 
increased from 6 to12% in urban areas and 4 to 6% in the rural areas. 
                 Atherosclerosis can affect all the arteries in the body leading to 
multiple consequences. CAD is a growing epidemic in the world because 
of the increase in sedentary lifestyle and increase in the consumption of 
high-fat, energy rich food . The number of younger individuals presenting 
with CAD is increasing today.
                  ST elevation myocardial infarction occurs when there is 
complete thrombotic occlusion of an already diseased coronary artery. 
Patient presents to the emergency department with chest pain. ECG 
2shows ST elevation in 2 or more contiguous leads. It is an emergency 
where treatment has to be initiated at the earliest as time means muscle.
               The thyroid is an important endocrine gland in our body. It has 
effects on almost every system in our body. The relationship between the 
thyroid and cardiovascular system is complex and present at many levels.
Hypothyroidism and hyperthyroidism are both known risk factors for 
the development of coronary artery disease. Thyroid disorders have also 
been implicated in influencing the outcome in heart failure, 
atherosclerosis, dyslipidaemia and arterial hypertension.
                  Any systemic illness can be associated with certain changes in 
the thyroid hormone levels.This is known as the Euthyroid sick syndrome 
or the low-T3 syndrome or non-thyroidal illness. This syndrome is 
characterised by a normal TSH, normal free T4 , reduced free T3 and 
increased reverse T3.
                 There are numerous prognostic factors for ST elevation MI 
such as the TIMI risk score, the LV ejection fraction etc. The thyroid 
status of a patient at the time of presentation to the hospital also affects 
the recovery. Patients with a sick euthyroid state at the time of 
presentation have a higher risk of complications- including heart failure, 
ventricular arrhythmias and death.
3AIMS AND OBJECTIVES
 To study the levels of TSH, fT3 and fT4 in patients presenting with 
ST elevation Myocardial Infarction
 To study the association, if any, between the presence of the Sick 
euthyroid state- characterised by reduced fT3 and normal TSH,fT4 
levels and the incidence of MACE (Major adverse cardiac events), 
namely ventricular arrhythmias, cardiac failure and death.
 To evaluate whether thyroid hormone profile can be used to predict 
prognosis in ST elevation myocardial infarction.
5REVIEW OF LITERATURE
ATHEROSCLEROSIS
              The term “atherosclerosis” was coined in Germany as 
“atherosklerose “in early 20th century. It was derived from the Greek
word athere and sklerosis meaning hardening of vessels.
               Atherosclerosis is the leading cause of mortality in the 
developed world today. Atherosclerosis refers to the formation of 
atheromas or fibrofatty plaques in the intima of blood vessels. These 
plaques protrude into vascular lumens and cause obstruction. They occur 
mainly in elastic arteries (e.g., aorta, carotid and iliac) and muscular 
arteries (e.g., coronary and popliteal arteries). Symptomatic disease 
usually occurs when atherosclerosis affects the arteries of the heart, brain, 
kidneys and extremities. Deposition of atherosclerotic plaques in the 
coronary arteries leads to coronary artery disease. Reduction in the blood 
supply to the myocardium alters the supply-demand ratio. This leads of 
ischemia of the myocardium. Certain conditions can aggravate ischemia 
by either increasing the cardiac energy demand (e.g.hyerptrophy) or by 
decreasing the oxygen bioavailability (e.g.anemia).
6ATHEROSCLEROSIS- RISK FACTORS
Advanced age, smoking, hypertension, diabetes mellitus, dyslipidaemia, 
sedentary lifestyle, metabolic syndrome, obesity are all important risk 
factors for atherosclerosis.
7SMOKING 
            Other than age, smoking is the most important risk factor for 
CAD. It is the leading preventable cause of death. The risk of CAD is 
directly proportional to the number of cigarettes smoked per day.
Smoking also increases the risk of ischemic stroke, sudden death, aortic 
aneurysm formation and peripheral vascular disease. In the past smoking 
used to be prevalent among men. However over the past few decades 
smoking has become increasingly prevalent among women. In young 
women who are on oral contraceptives, smoking has an adverse 
synergetic effect increasing the risk for CAD27,28.
              Smoking has acute undesired effects on blood pressure and 
sympathetic tone. It also accelerates atherosclerosis, enhances the 
oxidation of low-density lipoprotein (LDL) cholesterol and impairs 
endothelium-dependent coronary artery vasodilation. Smoking also 
contributes to adverse hemostatic and inflammatory effects including 
increased levels of CRP, soluble intercellular adhesion molecule-1
(ICAM-1), fibrinogen, and homocysteine. It also provokes spontaneous
platelet aggregation, increases monocyte adhesion to endothelial cells and 
adversely alters endothelial-derived fibrinolytic and antithrombotic 
factors, including tissue-type plasminogen activator and tissue pathway 
factor inhibitor.
8               Cessation of cigarette smoking remains the single most 
important intervention in the prevention of CAD27.
HYPERTENSION
               Hypertension remains the silent killer of our time. It remains 
underdiagnosed and undertreated. The prevalence of hypertension is also 
increasing and it confers a silent risk for CAD. Both elevated systolic and 
diastolic BP jointly contribute to cardiovascular risk. Reductions of blood 
pressure as little as 4-5mm hg have been shown to result in a large and 
clinically significant reduction in risk for stroke, CAD, peripheral 
vascular disease.
DYSLIPIDEMIAS
High LDL-C
               Elevations in Low density lipoprotein cholesterol confer an 
increased risk for CAD.LDL is intimately involved in the process of 
atherosclerosis. Patients with familial hyperlipoproteinemias with an 
elevated LDL are found to have accelerated atherosclerosis with early-
onset CAD, The current target LDL for patients with evidence of 
established atherosclerosis or Diabetes is <100mg/dl. Intensive treatment 
is recommended for the same38.
9The major risk factors, the presence of which can modify LDL target 
goals include-
 Cigarette smoking
 Hypertension (BP more than 140/90)
 Diabetes Mellitus
 Low HDL cholesterol (less than 40mg/dl)
 Family history of premature CAD- In male 1st degree relative  <55 
years, In female 1st degree relative <65 years
 Age >45 years for men, >55 years for women
 Lifestyle risk factors- obesity-BMI>30kg/m2, Physical  inactivity, 
Atherogenic diet
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RISK CATEGORY TARGET LDL (mg/dl)
Very High- ACS ,CAD with DM or 
multiple cumulative risk factors
<70
High-CAD or CAD risk equivalents <100
Moderately high- 2+ risk factors <130
Low risk- 0-1 risk factor <160
HDL cholesterol
             An inverse relationship exists between levels of HDL and the risk 
for CAD.HDL <40 md/dl is a major risk factor for CAD. The exact 
mechanism by which HDL cholesterol reduces the risk for CAD is not 
known.HDL functions in reverse cholesterol transport- it transports 
cholesterol from the peripheral tissues to the liver31. Hence it may ferry 
cholesterol out of the atherosclerotic plaques in the coronary arteries. It is 
also believed to be rich in antioxidant enzymes which may reduce the 
oxidised phospholipids in atheromatous plaques38.
11
METABOLIC SYNDROME, DIABETES MELLITUS AND INSULIN 
RESISTANCE
              Diabetes Mellitus is a major risk factor for CAD. Ischemic heart 
disease is the leading cause of death in diabetics. Patients with diabetes 
have an altered lipoprotein profile- also termed as diabetic 
dyslipidemia.Even though most diabetics have LDL cholesterol levels in 
the normal range, the LDL particles are smaller, denser and more 
atherogenic. HDL is low and TGL are elevated . Furthermore insulin 
resistance itself promotes atherosclerosis even before the development of 
overt diabetes. Hypertension also commonly accompanies diabetes and 
dyslipidaemia. This cluster of risk factors is also known as the metabolic 
syndrome29,30.
Metabolic syndrome- presence of any 3 of the following risk factors
 Abdominal obesity(waist circumference)  >102cm in men : >88cm 
in  women
 Fasting glucose >110mg/dl
 Triglycerides > 150mg/dl
 Blood pressure >130/>85 mm Hg
 HDL cholesterol   < 40mg/dl in men : <50mg/dl in women
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Therapeutic lifestyle changes (TLC) are a must for people with metabolic 
syndrome to counter the harmful effects of inadequate physical activity 
and obesity. The blood pressure goal in diabetic patients is 130/80 mm 
Hg.
OBESITY AND EXERCISE:
            The levels of physical activity have been shown to have an 
inverse relation to risk for CAD. Studies have shown that even modest 
exercise such as 30 minutes of walking every day reduces the risk of 
CAD and stroke. Exercise acts in multiple ways to reduce cardiovascular
risk. Aerobic exercise results in a mean reduction of BP by 5mm Hg. It
also leads to an increase in HDL cholesterol and a decrease in TGL. 
Though LDL concentrations are not affected by exercise, the average size 
of LDL particles is increased, hence making them less atherogenic. 
Exercise also improves insulin resistance and leads to better glycaemic 
control. It also helps lower CRP levels.
           Obesity, irrespective of activity levels is associated with increased 
vascular events. A higher BMI is associated with an increased risk of 
13
adverse cardiovascular events. Thus, weight management must play an 
important role in all cardiac preventive strategies.
MENTAL STRESS AND DEPRESSION
             The adrenergic surge associated with mental stress can increase 
myocardial oxygen requirements and aggravate myocardial ischemia. 
Stress can also lead to coronary vasoconstriction further reducing blood 
supply. Acute stress such as that associated with a natural disaster or an 
untoward event is also associated with increased risk. In today’s age, job 
related stress plays a very important role as more people are taking up 
high-profile, stressful jobs37.
              Depression is associated with an increased risk for CAD. This 
risk is independent of the greater prevalence of hypertension, smoking 
and lack of physical activity among patients with depression.
AGE AND GENDER:
               Increasing age is a non-modifiable risk factor for CAD.
Male gender is associated with an increased risk of CAD when compared 
to premenopausal women. After menopause, coronary risk accelerates in 
women26.
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                The protection in premenopausal women is probably due to the 
relatively higher HDL level which is due to the effect of estrogen on 
lipoproteins. However estrogen therapy in the postmenopausal age group 
has failed to demonstrate a net benefit in risk reduction25.
NOVEL MARKERS OF ATHEROSCLEROSIS
           Almost 50% of individuals who have a myocardial infarction have 
a normal lipid profile. Although the use of major risk factors for 
screening the general population is recommended, 20% of CAD events 
occur in patients who do not have even a single risk factor. There is a 
need to improve detection of people at risk of vascular events.
hsCRP
             Inflammation plays an important role in many stages of 
atherosclerosis. CRP or c-reactive protein is a simple downstream marker 
of inflammation which is now used as a cardiovascular risk marker. CRP 
is synthesised mainly from the liver but can also be synthesised by other 
tissues. It is still not clear whether CRP is just a marker of atherosclerosis 
or whether it contributes to the process. It appears to have some effects –
increase in the endothelial expression of plasminogen activator inhibitor 
15
type-1, reduced endothelial NO bioavailability, altered LDL uptake by 
macrophages and colocalisation with complement inside atherosclerotic 
plaques. Studies have shown that CRP measured by highly sensitive 
assays- hsCRP is a strong and independent predictor for adverse events-
MI, peripheral vascular disease and ischemic stroke. This is true even in 
patients with normal levels of LDL-C and plasminogen activator 
inhibitor. At all levels of LDL-C hsCRP has a prognostic value30.
HOMOCYSTEINE
            Homocysteine is an amino acid derived from the demethylation of 
methionine. Patients who have rare inherited defects of methionine 
metabolism develop severe hyperhomocysteinemia (plasma levels higher 
than 100 mol/liter).     They have a markedly increased risk of premature 
atherosclerosis and venous thromboembolism. Insufficient dietary folate 
intake can have mild to moderate elevations of homocysteine. 
Fortification of food with folate in industrialised countries has led to a 
reduction of patients with homocystinemia due to folate deficiency30.
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PATHOPHYSIOLOGY
                 The major determinants of oxygen demand of the myocardium 
are-heart rate, myocardial contractility and wall tension. The oxygen 
supply to the myocardium depends on the oxygen carrying capacity of 
blood (which depends on level of oxygen in inspired air, pulmonary 
function, haemoglobin concentration and function) and on coronary blood 
flow. Majority of the blood flow to the coronaries occurs during diastole 
and blood flow is phasic. To some extent, the myocardium can control the 
flow through coronaries by altering the resistance offered by the 
coronaries. There are 3 main types of resistance vessels- R1- large 
epicardial arteries, R2- prearteriolar vessels and R3- arteriolar and 
intramyocardial capillary vessels. In normal coronaries, majority of the 
resistance is determined by R2 and R3. The heart can regulate its blood 
flow by altering the level of resistance- this can occur as a response to 
emotional stress or exercise that increases the oxygen demand of the 
heart. This is known as metabolic regulation8. 
                  Physiologic alterations in blood pressure can also lead to 
alterations in the resistance of coronary blood vessels in order to maintain 
coronary blood flow at appropriate levels. This is known as 
autoregulation.
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                   Atherosclerosis causes narrowing of the lumen of the 
coronaries. Hence it limits the appropriate increase in blood flow in 
response to increased demand. If the luminal narrowing is severe, basal
blood flow is also affected and the patient can develop chest pain even at 
rest. With less severe narrowing, the patient is symptomatic during 
physical activity which increases the oxygen demand and the coronaries 
are unable to increase the blood flow appropriately.
              
             The normal functions of the endothelium are disrupted by 
hypertension, diabetes, dyslipidaemia- all of which are the main risk 
factors for atherosclerosis. Normally the endothelium is involved in 
control of vascular tone, it provides an antithrombotic surface and also 
controls inflammation and diapedesis. When these functions are lost, 
vasoconstriction occurs along with thrombus formation and inflammation 
with interaction between monocytes, platelets and the damaged, activated 
endothelium. All these changes lead to the deposition of fat, smooth 
muscle cells and intercellular matrix in the subintimal region. This leads 
to the formation of an atherosclerotic plaque. This process occurs at 
various rates throughout the vascular tree. However certain sites are more 
prone for these effects- these include sites of increased turbulence such as 
the branch points9. The degree of occlusion of the coronary artery can be 
correlated to the symptoms to some extent. When luminal narrowing is 
50%, the patient is unable to increase coronary blood flow when 
an increased demand. The patient develops chest pain on exertion. When 
the stenosis is >80%, blood flow at rest is also compromised and a further 
minor decrease in blood flow can lead to disastrous consequences.
               
THE EVOLUTION OF THE ATHEROSCL
18
EROTIC PLAQUE
there is 
19
                      When coronary narrowing is chronic and severe with 
recurrent episodes of myocardial ischemia, there is time for development 
of collateral vessels. These collaterals, when they are well developed can 
provide sufficient blood supply in the basal state but not when demand is 
increased, as in exercise11.
                       The term, Ischemic heart disease encompasses a wide 
spectrum of disease including  Angina pectoris, unstable angina, 
myocardial infarction, IHD with heart failure and sudden cardiac death.
                      Acute coronary syndrome is the common term given to ST 
elevation MI. Non-ST elevation MI and unstable angina. Both STEMI 
and NSTEMI are associated with elevation of cardiac biomarkers, 
whereas in unstable angina these biomarkers are normal. 
                      When the cap of an atherosclerotic plaque erodes or 
ulcerates, the plaque contents are exposed to blood. This exposes the 
highly thrombogenic subendothelial collagen to the platelets which 
adhere, aggregate and are activated10. They release potent aggregators 
like thromboxane A2, serotonin, platelet factor 3 and 4.This leads to 
vasospasm causing further narrowing and decrease in blood flow. Other 
factors released activate the coagulation cascade. This leads to the 
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formation of a fibrin rich thrombus and increases the bulk and stability of 
the thrombus and causes further reduction in blood flow. Soon the entire 
lumen of the coronary can be occluded. This is the basis of acute 
coronary syndromes.
ACUTE PLAQUE CHANGE:
The following changes can take place in a previously present plaque 
which may only be partially stenosing :
 Rupture or Fissuring
 Erosion or ulceration
 Haemorrhage into the plaque   
THROMBOTIC BALANCE OF THE ENDOTHELIAL CELL
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Intrinsic and extrinsic factors both play a role in triggering changes in 
plaque configuration. The composition of a plaque is dynamic. 
Vulnerable plaques are those which have a large number of foam cells, 
extracellular lipid, few smooth muscle cells, large number of 
inflammatory cells and a thin fibrous cap. These plaques are more prone 
to rupture8,9.
               Fissuring is more common at the site of the junction of the 
fibrous cap and the adjacent normal, atheroma-free coronary artery 
segment. Mechanical stress is maximum within the plaque at this site.
             Extrinsic factors such as adrenergic stimulation also play a role 
in acute plaque change. The surge in the adrenergic drive in the morning 
as soon as one awakes is one of the main reasons that acute MI occurs 
with a maximum incidence between 6 AM and 12 noon. Adrenergic drive 
causes a rise in blood pressure, thereby increasing physical stress on the 
plaque. Intense emotional stimuli can also contribute to acute plaque 
change39.
               Most of the acute changes seem to occur in plaques which 
produce only mild to moderate luminal stenosis. They are not severely 
stenotic or hemodynamically significant. This signifies that a large 
number of asymptomatic patients are at risk for developing acute 
coronary syndrome  as the plaque over which thrombus forms would 
22
have caused only mild obstruction before the event and hence the patients 
would have been asymptomatic prior to the event. At present there are no 
reliable methods by which we can predict plaque disruption or subsequent 
thrombosis10.
ROLE OF ACUTE PLAQUE CHANGE
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INFLAMMATION
                The inflammatory process plays an important role in every 
stage of atherosclerosis. The formation of the initial lesion requires 
interaction between leukocytes in blood and the endothelial wall. This
leads to the accumulation of macrophages and T-cells in the vessel wall. 
Release of chemokines by the endothelium  and increased expression of 
adhesion molecules like ICAM-1, VCAM-1, E-selectin and P-selectin 
leads to the entry of leukocytes into the vessel wall. Once the T-cells 
enter the vessel wall, they release cytokines like TNF,IL-6 and IFN-
gamma that further stimulate the endothelial cells and also activate 
macrophages which then take on the oxidised LDL and transform into 
foam cells8-10.
                   The fibrous cap is a dynamic structure that undergoes 
continuous remodelling. The major component is collagen which 
contributes to the strength of the cap. Collagen is continuously 
synthesised by smooth muscle cells and degraded by metalloproteinases 
secreted by macrophages. The balance between the synthesis and 
degradation of collagen determines the strength of the cap and hence the 
propensity to fissuring. Inflammation tends to destabilise the plaque by 
increasing the release of metalloproteinases by the macrophages. Because 
inflammation plays such an important role in atherosclerosis, markers of
24
inflammation like hsCRP in serum have been used as a predictor of risk 
of CAD.
CORONARY THROMBUS
                  Following plaque disruption, complete or partial thrombosis of 
the vessel occurs. If the thrombus superimposed on a disrupted plaque 
leads to total occlusion of the vessel it leads to the most serious form of 
ACS- transmural myocardial infarction. If the thrombus leads to an 
incomplete or partial obstruction ,it leads to subendocardial infarction and 
unstable angina9.
VASOCONSTRICTION
                  Vasoconstriction further aggravates the reduction in blood 
supply by narrowing the lumen and by increasing mechanical shear 
stress. Thus it can potentiate the process of plaque disruption. 
Vasoconstriction may be due to adrenergic agonists, released platelet 
contents like thromboxane A2, imbalance between endothelial relaxing 
(eg.nitrous oxide) and contracting ( e.g.endothelin) factors or due to 
mediators released from inflammatory cells
25
.
FUNCTIONAL AND METABOLIC CONSEQUENCES OF ISCHEMIA
                When a coronary artery is occluded partially or completely, 
along with the blood supply, the oxygen supply to the myocardium is also 
lost. Aerobic metabolism in the heart stops, the reserve stores of creatine 
phosphate are used up and soon the myocardium switches over to 
anaerobic glycosis. This leads to accumulation of lactate and other 
metabolites and acidosis develops. Soon  there is efflux of potassium into 
the extracellular fluid33.
MAJOR VASOCONSTRICTORS AND VASODILATORS
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Irreversible injury and myocyte death :
                Irreversible injury usually occurs when blood flow has been 
totally occluded in a vessel for more than 20 minutes and the area under 
risk is not supplied by collaterals. The injury starts in the subendocardial 
layer and progresses over time and involves the subepicardial layers33 .
This is because the subendocardium consumes more oxygen and the 
collateral flow is redistributed to the subepicardial layer of the heart. If 
there are conditions causing an increased oxygen demand (e.g.
Tachycardia) irreversible injury may occur earlier. Prior repeated 
episodes of reversible ischemia protect against irreversible injury to some 
extent through preconditioning35.
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                    In chronic CAD, the extent and magnitude of collateral 
vessels is the most important determinant of the time taken for 
irreversible injury. The area at risk for ischemia and the infarct size are 
inversely proportional to the size of collaterals. If the subendocardial 
flow can be maintained upto 30% of the basal flow by collaterals, 
irreversible injury may be delayed for more than an hour. 
PROGRESSION OF MYOCARDIAL NECROSIS AFTER COMPLETE CORONARY 
OCCLUSION
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If flow can be maintained upto 50% almost 5 hours may pass without 
significant necrosis.
               Reversible ischemia can be supply or demand induced ischemia. 
In supply-induced ischemia, coronary vasospasm or transient thrombosis 
in a critically stenosed coronary artery produces transmural ischemia.
                 In case of demand-induced ischemia, there is an inability to 
increase flow in response to increases in myocardial oxygen 
consumption. Hence ischemia predominantly affects the subendocardium. 
Both have different effects on myocardial diastolic relaxation. Supply-
induced ischemia causes an increase in LV compliance and demand-
induced ischemia decreases it. A stereotypical sequence of changes
develops during an episode of spontaneous transmural ischemia . 
Coronary occlusion results in oxygen desaturation33. This leads to a
decrease in ATP production. A fall in regional contraction occurs within 
several beats, reaching dyskinesis within 1 minute. As regional 
contraction come to a stop, there is a decrease in global LV contractility
(dP/dt) leading to a progressive increase in LV end-diastolic pressure, and 
a fall in systolic pressure. ECG changes including ST segment changes 
occur in 2 minutes as soon as the potassium efflux into the ECF reaches a 
critical level. Chest pain occurs at last and it is variable. When perfusion 
is restored the sequence of events is reversed. Chest pain is resolved in 
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the start followed by resolution of hemodynamic changes. However the 
contraction of myocardium can remain depressed –this reflects the 
development of a stunned myocardium33.
STUNNED MYOCARDIUM
                     If the restoration of blood supply occurs quickly, within 2 
minutes, contractile function also recovers immediately. However if the 
ischemia persists for a while or is more severe, then even after blood flow 
is completely restored, the myocardium does not regain full function 
immediately. This phenomenon is called myocardial stunning. This
occurs in the absence of myocardial necrosis. Stunning can also occur 
following demand-induced ischemia. Exercise-induced ischemia of the 
subendocardium distal to a coronary stenosis can lead to a depressed 
function that can persist for hours after the exercise is completed33.
                       Stunning may take upto 1 week to resolve. It is an 
important cause of reversibly dysfunctional myocardium following an 
acute event like ACS. Stunning is important to recognise as it will 
recover completely in the absence of further episodes of ischemia. The 
depressed contractility also normalises on stimulation with beta 
adrenergic agonists. At the cellular level, stunning probably is explained 
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by free-radical mediated myocardial injury and reduced sensitivity of the 
myocardium to calcium34,35.
PRECONDITIONING
                Preconditioning can be acute or chronic. Sometimes before a 
prolonged coronary occlusion occurs, an episode of brief reversible 
ischemia occurs. This serves to reduce the degree of myocyte necrosis. 
This phenomenon is known as acute preconditioning. When acute 
infarction is preceded by angina, preconditioning occurs , which is an 
endogenous mechanism that can delay the evolution of irreversible 
myocardial injury. Adenosine A1 receptor stimulation and the use of 
various agonists that stimulate protein kinase C or open K+-ATP 
channels can induce acute preconditioning.
                When preconditioning occurs on a chronic basis, it is known as 
delayed preconditioning. It helps in reducing infarct size and prevents the 
development of myocardial stunning.
                Once induced, delayed preconditioning can last upto 4 days. 
Protein synthesis with upregulation of the inducible form of NO synthase
(iNOS), cyclooxygenase 2 (COX-2), and opening of the mitochondrial
K+-ATP channel  is the mechanism of chronic preconditioning33.
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CHRONIC HIBERNATING MYOCARDIUM
           Any myocardial region where contractile function improves after 
coronary revascularization is defined as viable, dysfunctional 
myocardium. This spectrum of reversible dyssynergy includes three 
distinct categories. Function normalises completely after acute ischemia 
is rare in chronically dysfunctional myocardium.
           Prolonged moderate ischemia or brief periods of complete 
occlusion (short-term hibernation) result in post ischemic stunning in the 
absence of necrosis, with complete functional recovery occurring within 1 
week after reperfusion. This time course of functional recovery is 
dependent both on severity and duration of the ischemic episode34.
            Delayed functional improvement can also arise from structural 
remodelling of the heart that is independent of ischemia or a coronary 
stenosis. Examples include remote myocardial remodelling in heart 
failure or the reduced infarct volume that occurs over the initial weeks 
following coronary reperfusion.
           In patients with ischemic cardiomyopathy, chronic segmental 
dysfunction results from episodes of repetitive, often clinically silent 
ischemia over the territory supplied by one vessel.
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          When the resting flow to a dysfunctional myocardium distal to a 
fixed stenosis, relative to a normal segment of myocardium, is found to 
be normal, the myocardium is said to be chronically stunned. However if 
the relative resting flow is reduced then the myocardium is hibernating.
          The progression from chronically stunned myocardium to
hibernating myocardium is related to the functional significance of the 
chronic stenosis supplying the region .It is probably a reflection of its 
propensity to develop repetitive supply or demand-induced ischemia. 
This progression can develop in as soon as 1 week after a critical stenosis 
.As dysfunction progresses from chronically stunned to hibernating 
myocardium, the myocyte takes on regional characteristics similar to 
those from an explanted heart with advanced failure33-35.
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ANATOMY OF THE CORONARY CIRCULATION
The two main arteries supplying the heart are the right and left coronary 
artery arising from the aorta.These divide into a number of branches.
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                   The LCA originates from the left coronary sinus, it travels for 
1-2 cm and divides into 2 branches-the LCX and the LAD. The LAD 
descends in the anterior interventricular groove. The LCX runs along the 
left atrioventricular sulcus. Branches that arise in between these 2 are the 
diagonal branches.LCA supplies the left atrium, most of the left ventricle 
except the part near the posterior interventricular groove, small part of the 
right ventricle near the anterior interventricular groove and the anterior 
part of the interventricular system60.
                        The RCA originates from the right coronary sinus and runs 
in the right atrioventricular sulcus. The RCA supplies the Right atrium, 
most of the right ventricle except a small portion adjoining the anterior 
interventricular groove and a small part of the left ventricle adjoining the 
posterior interventricular groove. It also supplies the posterior part of the 
interventricular septum and the entire conducting system except the left 
branch of the AV bundle60.
                Among the coronary vessels, the epicardial arteries are 
maximally affected by atherosclerosis.  Stenosing plaques are found 
predominantly in the first few centimetres of the Left anterior descending 
artery (LAD) and the Left circumflex artery (LCX) and the entire length 
of the right coronary artery(RCA). 
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                 Any one of these major vessels or two of them or all three can 
be involved in atherosclerosis. Sometimes the process may also involve  
the major secondary epicardial branches like the diagonal  branches of 
LAD, posterior descending branches of the RCA or the marginal branch 
of LCX. However marginal branches are very rarely involved60.
CLINICAL FEATURES
              Patients commonly present with chest pain. Typical angina refers 
to left sided or retrosternal pain which is compressive or squeezing in 
nature, associated with palpitations or sweating, radiating to the jaw or 
either shoulder, hand and aggravated by exertion and relieved by rest. 
This is stable angina. The chest pain of myocardial infarction has similar 
characteristics but is more severe, may be associated with vomiting and a 
sense of impending doom and is not relieved with rest.
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Unstable angina refers to chest pain with at least one of three features: 
 occurs at rest (or with minimal exertion), usually lasting >10 
minutes
 more severe and of new onset (i.e., within the prior 4–6 weeks)
 it occurs with a crescendo pattern - distinctly more severe, 
prolonged, or frequently than before.
Non ST elevation myocardial infarction is the term used in a patient who 
presents with features suggestive of Unstable angina but who has elevated 
biomarkers of myocyte necrosis.
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         In diabetics silent MI is more common. In the elderly a MI may 
present with sudden-onset breathlessness or an episode of palpitations 
with syncope.
POSSIBLE OUTCOMES OF ACUTE PLAQUE CHANGE
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           On examination the patient is restless. He shows pallor with 
diaphoresis and cool extremities. In case of anterior wall MI patient may 
present with tachycardia and hypertension  due to sympathetic 
overactivity whereas in inferior wall MI patient presents with bradycardia 
due to parasympathetic overactivity40.
Myocardial Infarction can be classified into 5 types-
1. Spontaneous MI due to ischemia caused by a primary coronary 
event such as plaque erosion and/or rupture, fissuring, or 
dissection
2. MI secondary to ischemia caused by increased oxygen demand or 
decreased supply e.g., coronary artery spasm, coronary embolism, 
anemia, arrhythmias, hypertension, hypotension
3. Sudden unexpected cardiac death, including cardiac arrest, with 
symptoms suggestive of myocardial ischemia, accompanied by 
presumably new ST-segment elevation, or new LBBB, or 
presumably new major obstruction in a coronary artery by 
angiography and/or pathology, but death occurring before blood 
samples could be obtained, or before  the appearance of cardiac 
biomarkers in the blood
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4. A. MI associated with PCI
          B. MI associated with stent thrombosis, as documented by    
               angiography or autopsy                                                                                               
5. MI associated with CABG
DIAGNOSIS
               In a patient presenting with the typical history with risk factors, 
a 12-lead ECG can be used to make the diagnosis of acute coronary 
syndrome. Cardiac enzymes and various imaging modalities can be used 
to confirm the diagnosis in doubtful cases42.
               WHO and American Heart association requires at least 2 of the 
following 3 criteria for diagnosis of Myocardial infarction:
 typical symptoms of ischemia
 ECG changes
 Classical rise and fall in cardiac biomarkers.
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            When interpreting the tests used for diagnosis of MI this temporal 
sequence must be kept in mind. There are 4 main groups of tests used in 
diagnosis :
 ECG
 Cardiac biomarkers
 Cardiac imaging
 Nonspecific markers of inflammation and necrosis
ECG
           In the initial stage, when an epicardial artery is completely 
occluded, the ECG shows a ST segment elevation in leads overlying the 
infarcted area. The leads opposite the affected area will show a 
reciprocal ST segment depression.
As MI evolves, Q waves may form. The magnitudes of these Q waves 
vary and sometime they may be present only transiently.
          The evidence of an old MI on ECG may be just a loss of R wave 
amplitude with or without Q waves. On the other hand NSTEMI and 
unstable angina presents with ST-T changes other than ST segment 
elevation along with elevated cardiac biomarkers in NSTEMI and normal 
markers in UA.
41
CARDIAC BIOMARKERS 
               When a MI occurs and myocyte necrosis occurs, certain 
proteins present in myocytes are released into blood. The rate of this 
release depends on the molecular weight of the protein, their location 
intra-cellularly and the local lymphatic and blood flow. When the 
capacity of the cardiac lymph to clear the interstitial spaces of the infarct 
zone is exceeded, these markers spill over into venous blood.
                 The most commonly used cardiac biomarker today is cardiac 
specific troponin-I (cTnI)and troponin-T (cTnT). They have different 
amino acid sequences than their muscle counterparts.  Normally they are 
not detectable in blood41,42. After a MI, their levels can increase to >20 
times their normal limit. They remain elevated for 7-10 days.             
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               Creatine Kinase levels begin to rise in 4-8 hours and return to 
normal in 48-72 hours.CK-MB isoform is more specific for cardiac 
myocyte necrosis. It is mainly used for the diagnosis of reinfarction 
within the 1st week as troponins return to normal only after 7 days44,45.
CARDIAC IMAGING
            In 2-D Echocardiography, MI appears as abnormalities of wall 
motion. Though echo may not be able to differentiate between acute 
severe ischemia, an old myocardial scar and a STEMI, it is still a very 
useful instrument that can help with the diagnosis when ECG changes 
are not typical and also help in management decisions. It is simple and 
safe.
               Radionuclide imaging can also be used to diagnose STEMI, 
however they are rarely used as they lack the necessary sensitivity and 
specificity and are cumbersome.
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THYROID 
          The thyroid is an important endocrine gland in our body. It is one 
of the largest endocrine glands in the body and has capacity for 
tremendous growth. It has 2 lobes joined by an isthmus. Each lobe is 
4*2*2cm and the isthmus is 1.5* 2*0.5cm.The gland weighs around 15-
20gm in an average individual.
                   The right lobe is normally larger and more vascular than the 
left. The thyroid is supplied by 2 main pairs of arteries- superior thyroid 
artery from the external carotid and the inferior thyroid artery from the 
subclavian artery.
                The gland is composed of multiple spherical structures called 
follicles. At the centre of each follicle we have the proteinaceous 
substance called colloid. On cross section each follicle is lined by a 
single layer of thyroid cells surrounding the colloid. These cells are 
columnar when they are active and secreting, cuboidal when inactive.
The epithelium of the follicular cells has multiple microvilli at its apex. 
They extend into the colloid. Iodination, exocytosis and resorption of 
colloid occur at this surface. 20-40 follicles are grouped together by 
connective tissue septa and form lobules. The thyroid also has 
parafollicular or C cells that are derived from the neural crest and secrete 
calcitonin.
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THYROID HORMONE SYNTHESIS
              The function of the thyroid gland is to secrete thyroid 
hormones-Thyroxine (T4) and Triiodothyronine (T3) to meet the needs 
of the body. There are numerous steps involved in the synthesis of the 
thyroid hormones :
 Iodine trapping
 Oxidation of iodine to iodide
 Organification
 Release of hormones
Iodine Trapping
Synthesis of thyroid hormones requires adequate quantities of 
exogenous iodine. Dietary iodine intake must 
uptake of approximately 60
20 μg iodine as glucuronides and
STEPS IN THROID HORMONE SYNTHESIS
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allow for a 
-75 μg/day , for faecal losses of about 10
for urinary losses of 100 to 150 μ
thyroidal 
to 
g.
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         In the body iodine is mainly found in the form of iodide. In normal 
healthy adults, almost 90% of the dietary iodide is absorbed. Iodine 
intake varies from region to region depending on the soil and water 
content of iodine and also on dietary practices. Iodine deficiency is 
common in mountainous regions and in glaciated areas where the soil 
and water are poor in iodine content. In these places TSH induced 
compensatory enlargement of the thyroid is common- endemic goitre. In 
the body iodide is mainly concentrated in the extracellular fluid12.
            The normal concentration of iodide in the ECF is 10-15 ug/L.
The  iodide content in the thyroid gland in 8000 μg which is the 
maximum in the body. Hence iodide uptake into the thyroid has to take 
place against the concentration gradient and is an active process. This is 
enabled by means of a membrane protein -NIS-sodium iodide symporter. 
The transport of iodide depends on the presence of a sodium gradient 
across the basal membrane of the thyroid cell. The downhill transport of 
2 Na+ ions results in the entry of one iodide atom against an 
electrochemical gradient. The NIS is also found in other cells like the 
salivary and lactating mammary glands, choroid plexus, and gastric 
mucosa which concentrate iodine and in the cytotrophoblast and 
syncytiotrophoblast12.
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              This NIS can also transport perchlorate, thiocyanante and 
pertechnatate. This accounts for the use of potassium perchlorate to 
block iodine uptake in the treatment of hyperthyroidism. TSH 
stimulation increases the transcription and prolongs the half-life of NIS.
             In addition to iodine trapping, intracellular iodide can also be 
generated by the action of the enzyme- iodotyrosine dehalogenase 1 
(DEHAL1), also known as iodotyrosine deiodinase (IYD). IYD is a 
membrane protein concentrated at the apical cell surface that acts as a 
catalyst for the (NADPH)-dependent deiodination of MIT and DIT.The 
iodide thus released is immediately reconjugated to newly synthesized 
Tg after exiting the apical membrane of the cell. This process can be 
inhibited by the thiourea class of antithyroid drugs, including 
methimazole, carbimazole, and propylthiouracil (PTU) 12.
IODIDE OXIDATION AND ORGANIFICATION
                 Inside the thyroid the iodide is oxidised and the intermediate 
is incorporated into the iodothyrosines, Monoiodothyrosine and 
diiodothyrosine-MIT and DIT.This process is called organification.
Oxidation of iodide is mediated by the heme-containing enzyme 
TPO.The enzymes requires H2O2 generated by the calcium dependent
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DUOX1 and DUOX2 enzymes. This enzyme-protein is located in the 
apical membrane of the thyroid cells. The product of the peroxidation of 
iodide (i.e., the active iodinating form) may be free hypoiodous acid, I2, 
or iodinium (I+).This product is evanescent as it immediately reacts with 
the MIT and DIT within the Thyroglobulin in the colloid to form T3 and 
T4 respectively. This is also mediated by TPO.
COUPLING
       T4 and T3 are the hormonally active iodothyronines .MIT and DIT 
are precursors of the same.2 molecules of DIT combine to form T4, 
whereas one molecule of MIT and one DIT combine to form T3.
        The coupling reaction is the fusion of 2 DIT molecules to yield T4 
which has 2 diiodinated rings linked by an ether bridge. This process is 
catalysed by TPO. Normally every molecule of thyroglobulin contains 3-
4 molecules of T4 but only one in five molecules of thyroglobulin 
contains a T3 residue25.
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RELEASE OF THYROID HORMONE
              The thyroid gland is the only endocrine gland in the body to 
store its hormones in such large quantities.  The turnover rate is also very 
low-1% per day. This ensures that even when synthesis ceases 
completely, a euthyroid state can be maintained for upto 50 days.
                 The initial step in the release of thyroid hormones is the 
endocytosis of colloid containing the thyroglobulin into the cell. This is 
accomplished by pinocytosis. This process is stimulated by TSH. The 
endocytic vesicles now fuse with lysosomes and T3 and T4 are released. 
The iodotyrosine residues released within the lysosome are immediately 
acted upon by NADPH-dependent IYD and the iodine released is
recycled. The exact process by which the released thyroid hormones enter 
the blood stream is not known but the transporter MCT8 is believed to 
play a role51.
                        The normal ratio of T4 to T3 in thyroglobulin is 15:1 
whereas in the serum it is 10:1.This implies that some of the T4 
immediately after release from the thyroglobulin is acted upon by 
deiodinase and converted into T3 before release into the bloodstream.
                        T4 release from the thyroid can be inhibited by iodide. The
exact mechanism is not known but excess iodination of thyroglobulin can 
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make it resistant to hydrolysis. Also iodide inhibits the stimulation of 
thyroid adenylate cyclase by TSH.
REGULATION OF THYROID HORMONE SECRETION
        The regulation of thyroid hormones is a classic example of a 
feedback loop. Thyrotropin releasing hormone (TRH) is a modified 
tripeptide released by neurons in the hypothalamus. TRH is synthesised 
by neurons in the parvocellular region of the paraventricular nuclei of the 
hypothalamus. The gene encoding TRH has elements responsive to 
glucocorticoids, cAMP for mediating TRH release and for negative 
feedback by thyroid hormones. After synthesis TRH travels along the 
axons of hypothalamic-pituitary plexus through the median eminence and 
is released in the portal system formed by the hypothalamic-pituitary 
plexus44.
           Axons containing catecholamine, Melanocyte stimulating 
hormone, Leptin agouti related peptide, somatostatin all innervate the 
neurons that synthesise TRH and influence the rate of synthesis and 
release of TRH.
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          T3 suppresses the production of  TRH by inhibiting the production 
of pre-pro-TRH. It also blocks the ability of TRH to stimulate the 
synthesis and release of TSH from the thyrotrophs45. 
           
REGULATION OF THYROID HORMONE SYNTHESIS
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    TSH is a glycoprotein hormone secreted by the thyrotrope cells 
situated in the anterior pituitary. It plays an important role in the 
regulation of the thyroid axis. It has 2 subunits- alpha and beta.            
                     The beta subunit is unique to TSH whereas the alpha is 
common to TSH, LH, hCG and FSH. Glycosylation of the protein is 
essential to prevent its intracellular degradation and for its full biologic 
activity. Glycosylation of the TSH molecule requires TRH. Secretion of 
TSH shows a circadian rhythm with peak levels in the night before sleep.
             Removal of the hypothalamus is not associated with as severe 
thyroid dysfunction as that seen after hypophysectomy. This shows that 
T3 and T4 both have a negative feedback on TSH secretion, however 
TRH sets the set point for this feedback.
            Somatostatin, dopamine, bromocriptine all cause inhibition of 
TSH release on an acute basis.
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TSH STIMULATORY AGENTS TSH INHIBITORY AGENTS
TRH
Alpha-adrenergic agonists
Prostaglandins
Opioids
Arginine vasopressin
Glucagon like peptide (GLP-1)
Galanin
Leptin
Thyroid hormones & analogues
Dopamine & its agonists
Gastrin
Serotonin
Cholecystokinin
Gastrin-releasing peptide
Neuropeptide-y
IL-1beta, IL-6
TNF-alpha
Bexarotene
Phenytoin
Somatostatin & analogues
     
  TSH acts on almost every step in the synthesis of thyroid hormones. The 
TSH receptor (TSH-R) is present on the cell surface of the thyroid cells.
This receptor protein consists of a large extracellular N-terminal domain, 
7 membrane-spanning domains, and an intracellular domain that 
transduces the signal by phosphorylation of the α-subunit of G proteins.
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            The TSHR mainly couples to the stimulatory protein, Gs. 
However, when activated by high concentrations of TSH (100 times the 
physiologic level), it can also couple to Gq/G11, activating the inositol-
phosphate diacylglycerol cascade.
 Signalling via the phospholipase C (PLC) and intracellular Ca2+
pathways- leads to regulation of iodide efflux, H2O2 production, 
and Tg iodination
 Signalling via the protein kinase A (PKA) pathway mediated by 
cAMP – leads to regulation of iodine uptake and transcription of 
Tg, TPO, and NIS mRNAs- leads to thyroid hormone production .
The TSHR also binds with thyroid-blocking antibodies and neutral 
antibodies to the TSHR46. Lutenising hormone and human chorionic 
gonadotropin can also bind to the TSHR and lead to its activation- this is 
the cause for the physiological hyperthyroidism in pregnancy.
TRANSPORT AND METABOLISM OF THYROID HORMONES
                   Both T3 and T4 are bound to albumin, thyroid binding 
globulin (TBG) and transthyretin (TTR) in the serum. This binding leads 
to decreased clearance, increased circulatory pool and selective delivery 
to tissues.
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                  TBG has very high affinity towards thyroid hormones. So
even though it is present in small quantities (1-2mg/dl), it carries upto 
80% of the total thyroid hormones in serum. Albumin is present in large 
quantities (3.5g/dl) but has lesser affinity. It binds 30% of T3 and 10% of 
T4. TTR binds 10% of T4 and very little T3.Upto 99.98% of T4 and 
99.7% of T3 is present in the bound form with proteins. A greater 
fraction of T3 is unbound but the total T3 is less than T4 and is cleared 
more rapidly than T4.
               The free form of the hormones is the active form. When a 
change in TBG occurs, to maintain the free T4 and T3 concentrations at 
the normal level, the bound hormone changes in the same direction. For
example, when we administer estrogen , TBG concentrations are 
increased with a reduction in free T4.This leads to a decrease in T4
clearance, allowing an increase in the plasma total T4 concentration.
This interactive process eventually brings the free T4 levels to normal at 
a new equilibrium without a change in T4 secretion rate. The transient 
fall in free thyroid hormones also slightly decreases the negative 
feedback on the hypothalamic-pituitary-thyroid axis. This whole process 
is known as the free thyroid hormone hypothesis.
                  The entry of the thyroid hormones into cells is mediated by 
various membrane transporters. Some of the important ones are 
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Monocarboxylate transporter 8 (MCT8) and organic anion transporting 
polypeptide 1C1(OATP1C1).Defects in MCT8 have been shown to be 
associated with a severe neurologic disease.OATP1C1 is believed to be 
involved in the transport of thyroid hormones across the blood brain 
barrier.
IODOTHYRONINE DEIODINATION
Metabolism of both T3 and T4 occurs mainly via deiodination by a 
group of selenium-containing deiodinases. Hence T4 undergoes 
monodeiodination of its external ring (5’) to the active thyroid hormone,
T3. This reaction is catalysed by both D1 and D2.This is the main source 
of almost 80% of the circulating T3 in humans16.
            Inner ring deiodination leads to inactivation of the hormones and
is catalysed primarily by D3, which inactivates T3 and converts T4 to 
rT3.
          The three human deiodinases are structurally similar. They are all 
homodimers  and they contain the amino acid selenocysteine in the
active catalytic center. Selenium is believed to be the iodine acceptor 
during these reactions.
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               D1 catalyses both 5′ and 5 deiodination of T4 to form T3 and 
rT3, respectively. However the Michaelis-Menten constant (Km) for 
these reactions is approximately 3 orders of magnitude greater than that 
of D2 and D3 for this substrates16. 
      The preferred substrates of D1 are rT3 (5′ deiodination) and T3SO4
(5 deiodination). D1 can be inhibited by PTU, unlike D2 and D3. 
D1levels are markedly increased when thyroid hormone levels are high
through increased gene transcription. On the other hand D2 mRNA and 
protein are reduced by increase in thyroid hormones. D2 has a very short 
half-life of only 20 to 30 minutes, whereas that of D1 and D3 is more 
than 12 hours. This is because D2 undergoes rapid ubiquitination, a 
process that is accelerated by interaction with its substrate T4 or rT3. 
                  
THE SUBSTRATES AND PRODUCTS OF THE 3 DEIODINASE ENZYMES
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                  D2 is located close to the nucleus intracellularly and the T3 
formed by its catalytic action has better access to the nucleus than that 
formed by D1.It can easily enter the nucleus and carry out its actions. D1 
is located in the plasma membrane and the T3 produced by this enzyme
is usually secreted into the plasma. The action of D2 is especially 
important in the maintenance of the hypothalamic-pituitary axis. As the 
levels of T4 falls, the levels of D2 increase much before the serum T3 
falls16-18.
THYROID HORMONE ACTIVATION AND INACTIVATION IN A CELL 
EXPRESSING D2 AND D3
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PARAMETER D1 D2 D3
Physiological Role rT3 &T3SO4
degradation, source 
of plama T3
Provides 
intracellular T3 
in some tissues, 
source of plasma 
T3
Inactivates T3 
and T4
Tissue Location Liver, Kidney,
Thyroid,
?Pituitary
CNS, Pituitary, 
Brown adipose 
tissue, thyroid, 
placenta, skeletal 
muscle, heart
Placenta,CNS,
Fetal and adult 
liver, skeletal
muscle,
Hemangiomas
Subcellular 
Location
Plasma Membrane Endoplasmic 
reticulum
Plasma 
Membrane
Preferred substrate rT3,T3SO4 T4,rT3 T3,T4
Susceptibility to 
PTU
High Absent Absent
Response to 
increased T4
Increase in levels Decrease in 
levels
Increase in 
levels
Km rT3, 10−7; T4, 10−6 10−9 10−9
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MECHANISM OF THYROID HORMONE ACTION
            Thyroid hormones act by binding to a specific nuclear thyroid 
hormone receptor (TR).This complex now binds to DNA, usually as a 
heterodimer with retinoid X receptor (RXR).The binding takes place at 
specific sequences called thyroid hormone response elements, or TREs. 
The DNA binding-site preferences of the RXR-TR (or TR-TR) complex
determines the binding11.
            As T3 has a 15-fold higher binding affinity for TRs than T4, it 
functions as the active thyroid hormone. In humans, 2 TR genes are 
found, α and β. They are present on chromosome 17 and 3, respectively. 
When these genes are alternatively spliced many products are formed, 
both active and inactive. The active proteins are TRα1, TRβ1, TRβ2, 
and TRβ347,48.
             The protein structure of TRs has 3 major functional  domains—
one that binds DNA, one that binds ligand, and a major transcriptional 
activation domain in the C-terminus.
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Various tissues express each of these receptors.
 TRα especially TRα2 is important in the hypothalamus and 
pituitary for regulation of thyroid axis.
 TRβ2 is expressed in the cochlea.
 TRα1 is expressed in all tissues- however mRNA is especially 
highly expressed in the kidney, liver, brain and heart.
 TRα3 is expressed in lungs, liver and kidneys
Studies have shown that TRβ is involved in the feedback regulation of 
thyroid hormone effects and cochlear development, whereas cardiac 
function and energy metabolism are more likely to be regulated by 
TRα47,48.
THYROID FUNCTION IN ILLNESS AND FASTING
           Fasting and illness are associated with a number of changes in 
thyroid function which are similar in both conditions.
           There is a central reduction in TSH secretion with a decreased T3 
level in plasma and decreased binding of T4 and T3 in serum .This 
pattern of findings in the clinical background of illness is termed the 
euthyroid sick syndrome or low T3 syndrome. There is a reduction in 
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serum fT3 with a corresponding increase in rT3.In the initial stages there 
is no change in the levels of fT4 or total T4 or TSH50.
The exact mechanism behind the sick euthyroid syndrome is not known. 
Various mechanisms have been proposed. These include :
 modifications to the hypothalamic–pituitary axis
 altered binding of thyroid hormone to circulating binding proteins
 modified entry of thyroid hormone into tissue
 changes in thyroid hormone metabolism due to modified 
expression of the intracellular iodothyronine deiodinases
 Changes in thyroid hormone receptor (THR) expression or 
function. 
               Variations in the levels of various deiodinases are proposed to 
play a role. Decrease in D1 and D2 mediated conversion of T4 to T3 with 
an increase in D3 levels in liver and muscle leading to increased 
formation of rT3 from T4 and 3,3′ diiodothyronine from T3 have been 
noted in many studies.
                 In mice with genetically absent D1 and D2, levels of T3 were 
maintained. This suggests that normally the regulation of serum T3 levels 
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is under strict control with multiple compensatory mechanisms in place. 
However during fasting or illness, all compensatory mechanisms are 
reduced, probably mediated by the hypothalamus and the T3 levels fall.
                This fall in T3 levels may be beneficial for the patient while 
fasting or during illness. The fall in T3 contributes to a reduction in the 
basal oxygen consumption and heart rate and contributes to a negative 
nitrogen balance, all of which are beneficial during fasting52,53. If the 
illness progresses, a series of changes takes place. There is further 
suppression of the HPA axis with reduction in fT4 levels. This signals the 
development of a complex syndrome with worsening prognosis as fT4 
levels decrease further. In the brain there is a reduction in TRH mRNA in 
the paraventricular nuclei. There is also increased conversion of T4 to T3 
by D2 in the tanycytes lining the 3rd ventricle. This leads to a blunted 
response of TSH to the fall in T3 and T4 levels58. This is seen mainly 
with infections and may be because of the increased levels of cytokines 
such as IL-6.All these changes may be further aggravated by drugs used 
commonly in the treatment of serious illnesses- like dopamine and 
glucocorticoids that further suppress the TRH-TSH axis56.
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Severity of 
Illness
fT3 fT4 rT3 TSH Proposed 
mechanism
Mild N N Decreased 
D1,D2
Moderate N or N or Further 
decrease
In D1,D2 
with 
?increase 
in D3
Severe Further 
decrease
In D1,D2 
with 
?increase 
in D3
Recovery Not 
known
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                The neurons of the paraventricular nucleus (PVN) that secrete 
TRH are innervated by neurons from the arcuate nucleus (ARC) that
contain melanocyte-stimulating hormone (MSH), neuropeptide Y (NPY), 
agouti-related protein (AGRP), and the inhibitory neurotransmitter 
GABA. Both NPY and AGRP inhibit TRH gene expression, an action 
prevented by leptin. During fasting, when leptin decreases, the inhibitory 
actions of NPY of AGRP can prevail leading to diminished TRH. The 
expression of TRH in the PVN is stimulated by MSH, and this effect is 
enhanced by leptin57. Thus, in fasting (low leptin), the stimulatory action 
of MSH on TRH expression in the PVN is diminished.
MODIFICATION OF THE HPA AXIS DURING FASTING/ ILLNESS
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                  T3 produced by deiodinase D2 in tanycytes has important
feedback inhibitory actions on TRH production in the PVN58. During 
sepsis and trauma, there is an increase in tanycyte D2, which is postulated 
to lead to an increased generation of T3 from T4. Tanycyte processes 
may extract T4 from portal capillaries, blood vessels in the arcuate
nucleus or the CSF (in the third ventricle). The T3 can then be released 
back into the CSF or the blood stream. TRH neurons may take up T3 via 
diffusion from the CSF, by axonal terminals of the TRH neurons present 
in the median eminence, or the release of T3 into the arcuate nucleus may 
influence the activity of arcuate neurons that project into the PVN56.
                  Irrespective of the mechanism under play, the sick euthyroid 
state is associated with a poor prognosis. Treatment of the sick euthyroid 
state with T3 or TRH is associated with biochemical improvement.
However no improvement has been seen in the clinical state or prognosis.
Hence at present no treatment is recommended for the sick euthyroid 
state.
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LABORATORY I NVESTIGATIONS USED FOR THE EVALUATION 
OF THYROID DISORDERS:
 Tests of the hypothalamic-pituitary-thyroid axis- measurement of 
TSH, Total T4,T3, FreeT3,T4
 Tests that measure the metabolic impact of thyroid hormones-
Basal Metabolic rate, Serum LDL cholesterol
 Tests that help determine etiology- Thyroid autoantibodies
 Radioiodine uptake and thyroid scanning
 Ultrasound of the thyroid
Quantitation of the TSH and Thyroid hormone levels:
Measurement of TSH levels is the most widely used screening test for 
detection of thyroid disease. This is because TSH secretion is extremely
sensitive to the plasma concentrations of free thyroid hormones, thus it 
provides a precise and specific barometer of the thyroid status of the 
patient.
         The immunometric assay is most commonly used as it is more 
sensitive and specific than the radioimmunoassay. In this assay, the TSH 
molecule is used to link a TSH antibody bound to an inert surface (e.g., 
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particles, the side of a test tube) to a second antibody (directed against a 
different TSH epitope).This 2nd antibody is labelled with a detectable 
marker such as 125I, an enzyme, or a chemiluminescent reagent. The 
concentration of TSH in the serum is proportional to the intensity of the 
signal generated.
When the TSH values are abnormal, T3 and T4 measurements must be 
done next to confirm the abnormality. Total T3 and T4 can be measured 
sensitively and specifically by radioimmunoassay.
The thyroid status of a patient depends on the concentration of the free 
hormone rather than the total hormone levels. Hence measurement of fT3 
and fT4 may be necessary in some cases. Direct measurements of the 
concentrations of fT4 and fT3 in serum, which are most accurate are 
performed by assay of these hormones in a dialysate or ultra-filtrate of
serum. This is impractical and hence alternative methods have been 
developed12.
Two categories of methods are used- comparative free T4 methods and 
FT4 Index methods
69
The Thyroid hormone binding ratio (THBR) - This is derived from the 
T3-resin uptake test. Here the distribution of radiolabeled T3 between the 
unoccupied thyroid hormone binding proteins in the sample and an 
absorbent resin is determined. The binding of the labelled T3 to the resin 
is increased when there is reduced unoccupied protein binding sites (e.g., 
TBG deficiency) or increased total thyroid hormone in the sample; it is 
decreased under the opposite circumstances9.
The free T4 index: This is obtained by finding the thyroid hormone–
binding ratio (THBR) and multiplying that result by the total T4 (or T3). 
In this test, a tracer quantity of labelled T4 (or T3) is added to serum,
which is then exposed to a solid phase matrix coated with T4 or T3 
antibody or to an inert matrix that binds the iodothyronine irreversibly. 
The proportion of labelled T4 or T3 bound by the solid phase is then 
quantitated. This value, like the free fraction of T4 quantitated directly in 
a dialysate, varies inversely with the concentration of unoccupied TBG 
sites in the serum8.
THE THYROID HORMONE AND THE CARDIOVASCULAR 
SYSTEM: Cardiovascular diseases have similar pathophysiologic 
mechanisms which lead patients from risk factors, such as dyslipidaemia, 
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smoking, high blood pressure etc. to congestive heart failure and finally –
to death.
                Thyroid Hormones have multiple effects on the cardiovascular 
system and also on the important cardiovascular risk factors like 
hypertension and dyslipidaemia.
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The treatment of CAD also becomes complicated when a thyroid disorder 
is associated with the CAD. Hence thyroid hormones have an impact on 
cardiovascular diseases right from the risk factors and pathogenesis up to
the treatment modalities13.
EFFECTS OF THE THYROID HORMONE ON THE NATURAL 
HISTORY OF CAD:
Effects on Cardiomyocytes :
On the genome level (long term effects )– T3contributes to
 Synthesis of proteins and activation of transcription of the genes 
for alpha-isoform of myosin heavy chain, sarcoplasmic reticulum 
Ca activated ATPase, alpha1-adrenergic receptors, guanine-
nucleotide-regulatory proteins, Na+/K+-adenosine triphosphatase, 
some of voltage gated K+ channels4.
 repression of transcription of the genes for the beta-isoform of 
myosin heavy chain, phospholamban, nuclear receptor alpha1
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Extra nuclear cellular effects (short term)
Membrane effects
 Augments the activity of the 
SA node by increasing the 
conductance density of I(f)-
channels 
 Activates the transmembrane 
transfer of sodium and 
potassium, glucose and 
calcium
Increases the heart rate and oxygen 
demand of myocardium
cardiomyocytes’ metabolism
activated
sarcoplasmic reticulum effects
 Activates  calcium reuptake 
in diastole, up-regulates of 
Ca-activated ATPase, down-
regulates phospholamban
expression
Augments contraction of 
cardiomyocytes, enhances
myocardial relaxation
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OTHER EFFECTS THAT INFLUENCE THE NATURAL HISTORY 
OF CAD
Effects on heart:
Increases the density of Beta1-
adrenoreceptors in the heart & the 
response to
catecholamines
Increase in cardiac output
Effects on vascular wall:
Causes Relaxation of vascular 
smooth muscle cells.
Vasodilatation, decreases preload 
as well as afterload on the heart, 
decreases the peripheral vascular 
resistance
Metabolic effects
Activates metabolism Increases oxygen demand of 
myocardium
Effects on lipid profile Maintaining serum VLDL,LDL and 
HDL cholesterol, triglyceride and
apo-B 100 levels within normal 
range
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Modulates the production of 
glucose and storage of glycogen in 
the liver and heart
Cardiomyocytes’ metabolism
activated
Increases reabsorption of sodium in 
the kidney
Increases circulation blood volume
HYPOTHYROIDISM AND CAD:
Overt hypothyroidism is associated with hyperlipidemia, coagulation 
abnormalities, endothelial dysfunction, hypertension, LV hypertrophy,
diastolic dysfunction of heart ventricles, and abnormalities of insulin 
resistance. All of these factors can alter the atherosclerotic process and 
modify morbidity and mortality rates for CAD4.
Hypothyroidism and Hyperlipidemia:
Hypothyroidism leads to elevated plasma total cholesterol and LDL
cholesterol levels. Elevation of TGL is also seen along with increased 
concentration of HDL cholesterol (mainly because of elevated 
concentration of HDL–2 particles). Hence, the lipid profile in patients 
with hypothyroidism is associated with atherogenic properties, and may 
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be characterized by the unusual condition with simultaneously elevated 
TGL and HDL cholesterol levels. This elevated plasma concentration of 
HDL cholesterol may partly diminish the atherogenic lipid profile in
patients with overt hypothyroidism. Patients with hypothyroidism also 
have increased concentration of lipoprotein (a) which is highly 
atherogenic4.
Hypothyroidism and Hypertension:
           The prevalence of hypothyroidism among the general population 
of patients with hypertension is around 3-4%. Patients with 
hypothyroidism and hypertension have higher blood pressure levels 
compared with those without thyroid dysfunction.
At the same time hypertension is more common in hypothyroid patients
– its prevalence reaches 20-40%. So, hypertension is frequently 
associated with hypothyroidism. Hypothyroidism is associated with
predominantly diastolic hypertension4. This is believed to be a result of 
increased systemic vascular resistance, increased arterial stiffness and 
impaired endothelial function.
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HYPERTHYROIDISM AND CAD:
Hyperthyroidism affects the natural history of CAD in many ways. 
Primarily it increases myocardial oxygen demand along with sinus and/or 
supraventricular tachycardia (as well as atrial fibrillation) – these factors 
can contribute to decompensation of underlying CAD and lead to 
manifestation of angina pectoris and heart failure (mostly with high 
cardiac output). Furthermore, systolic BP is usually increased, while 
diastolic BP is decreased in patients with hyperthyroidism. This causes 
the pulse pressure to become wider and mean blood pressure becomes
moderately decreased4.
         Hence there is an increase in cardiac output with a reduction in 
peripheral vascular resistance; resulting in the classic hyperdynamic 
cardiovascular status. Hyperthyroidism affects another aspect of the 
cardiovascular system, the renin-angiotensin aldosterone system. This is 
activated in patients with thyroid hyperfunction. This contributes to the 
hypertension and the ventricular remodelling4.
          Hyperthyroidism is also associated with an increase in                         
von Willebrand factor levels as well as enhanced function of platelets and 
thus, a reduced collagen epinephrine- induced closure time (platelet plug 
formation measure). This may lead to increased platelet aggregation.
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            On the other hand, the presence of CAD may compromise the 
ability of myocardium to respond to the metabolic demands of 
hyperthyroidism. Hyperthyroidism may lead to MI even in patients
without coronary stenosis. In hyperthyroid patients above 50 years of age
on treatment, cardiovascular complications are the leading cause of 
death4.
            Dysrhythmias (especially atrial fibrillation) with thromboembolic
complications and hypertension are the most important confounding 
factors for cardiovascular morbidity and mortality in hyperthyroid 
patients 
THE EFFECT OF SICK EUTHYROID STATE ON PROGNOSIS OF 
ACUTE MYOCARDIAL INFARCTION.
Acute myocardial infarction is a leading cause of mortality in the world 
today. There are multiple scoring systems and factors used to 
prognosticate patients with STEMI. Systems like the TIMI- thrombolysis 
in Myocardial infarction score are commonly used.
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However, the presence of the sick euthyroid state at the time of 
admission or within the first 3 days is an independent prognostic indicator 
that can be used to predict higher rates of mortality and major adverse 
cardiac events like ventricular arrhythmias and cardiac failure. 
The pathogenesis is probably multifactorial. The role of some cytokines 
has been studied. These cytokines are also elevated in patients with 
STEMI. There appears to be a negative correlation between the elevation 
of these cytokines- CRP and IL-6 and the fall in fT3 levels6.
In patients with prior angina, the sick euthyroid state may be present even 
before the acute event and when this is the case, may play a protective 
role when MI occurs. This is because the decreased fT3 helps to reduce 
the oxygen demand of the myocardium55.
However if the sick euthyroid state develops after the acute STEMI, it is 
actually associated with higher mortality rates and poor prognosis. The 
mechanism by which thyroid dysfunction leads to a worse prognosis is 
not known completely. Thyroid hormones can affect ventricular function
through stimulation of sarcoplasmic Ca-ATPase activity and expression.
This ATPase removes the calcium from the cytoplasm during diastole and 
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allows for the uncoupling of actin-myosin cross-bridging. Hence it plays 
a major role for diastolic function of the heart. It is also involved in the 
regulation of the quantity of calcium in the sarcoplasmic reticulum. This
calcium is needed for systolic contraction and is thus, also important for 
the systolic heart function. When there is a downregulation of the thyroid 
hormone system in the short term in STEMI, the change in intracellular 
calcium handling may contribute to myocardial stunning and reperfusion
injury due to calcium overload. Down-regulation of the thyroid hormones
also leads to an increase in systemic vascular resistance and increases the 
cardiac afterload. In an already weakened heart, the cardiac output will be 
reduced55.
                         
                        The Sick Euthyroid State is also seen in patients with 
chronic heart failure and in patients who go into cardiac arrest and are 
revived. Hence the thyroid hormone affects the cardiovascular system at 
multiple levels and in multiple ways. Hence it is prudent to screen every 
patient with CAD for the presence of thyroid dysfunction as this has an 
effect on treatment and prognosis.
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MATERIALS AND METHODS
PARTICIPANTS
75 Patients admitted with ST elevation Myocardial Infarction at Govt. 
Rajaji Hospital  >18 years of age fulfilling all the inclusion criteria .
STUDY POPULATION:
The study was conducted among 75 patients admitted in Government
Rajaji Hospital with history, clinical features and ECG changes of  ST 
elevation Myocardial Infarction.
INCLUSION CRITERIA:
 Age > 18 years
 History of chest pain with ECG changes of ST elevation 
Myocardial Infarction.
EXCLUSION CRITERIA:
 Patients presenting as Non ST elevation MI or unstable Angina
 Known case of hypothyroidism/hyperthyroidism
 Known case of any other endocrine disorder excluding Diabetes 
Mellitus
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 Known case of Chronic Kidney disease
 Known case of Chronic Liver disease
 Known case of malignancy
 Patients with Renal failure
 Patients taking amiodarone, steroids , propranolol ,oral 
contraceptives
 Patients who have received iodinated contrast in past week
DATA COLLECTION :
          A previously designed proforma was used to collect the 
demographic and clinical details of the patients. A detailed history was
taken and a complete clinical examination was performed. ECG was 
taken at the time of admission. Blood samples for thyroid profile were
taken at the time of admission. Clinical course of all patients were
followed up till discharge.
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LABORATORY INVESTIGATIONS
Blood samples for analysis of TSH, fT3 and fT4 were taken at the time 
of admission. Samples were taken in a container with no added 
anticoagulant. Serum was analysed for the levels of TSH,fT3 and fT4 by 
chemiluminescence method.
The reference levels used were :  Serum fT3 – 2.3 – 4.2 pg/ml
                                                   Serum fT4-  0.89 – 1.76 ng/dl
                                                  Serum TSH – 0.35 – 5.50 mIU/ml
STUDY PROTOCOL : 
 Patients with ECG changes suggestive of ST elevation MI were 
included in the study. 
 Serum fT3, fT4 and TSH were analysed for all the patients. 
 Depending on the thyroid profile, patients were divided into 3 
groups- those with a normal thyroid function- controls, those with a 
hypothyroid profile (decreased fT3/fT4 and/or elevated TSH) and 
those with a sick euthyroid state ( normal fT4,TSH and low fT3 ).
 All the 3 groups were followed up till discharge.
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STUDY DESIGN : Prospective analytical study.
DATA ANALYSIS : All the data was entered onto Microsoft excel sheet 
2010 version. The  statistical analysis was done using SPSS software. The 
statistical tools applied were mean, standard deviation, and chi – square 
test with Yates’ correction. The results were considered  very significant 
with p value < 0.01 and significant with  p value <0.05.
PERIOD OF STUDY :
September 2013 to August 2014
COLLABORATING DEPARTMENTS : Department of General 
Medicine, Department of Cardiology, Department of Endocrinology
ETHICAL CLEARANCE : obtained
CONSENT :Individual written and informed consent
ANALYSIS : statistical analysis- chi square
CONFLICT OF INTEREST : NIL
FINANCIAL SUPPORT : NIL
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OBSERVATION AND RESULTS
Table 1-Age distribution of the study population
Age interval Number of 
Euthyroid
Number of Sick 
euthyroid
Number of 
Hypothyroid
Total
31-40 2 1 - 3
41-50 9 6 - 15
51-60 31 6 5 42
>60 10 2 3 15
Total 52 15 8 75
Myocardial infarction is more common in the 5th and 6th decade with 
more cases in the 6th decade. The youngest patient was 33 years old and 
the oldest was 80 years old.
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Comment :    
Mean Age of patients (± SD) - Males – 52.25 (±6.42) years
                                                 Females – 60.88 (± 4.81) years
                                                 Sick Euthyroid patients- 52 years
                                                    Controls (Euthyroid patients)-55.76 years 
                                                 Hypothyroid patients- 59 years    
  
The mean age was higher in females 60.88 compared to males 52.25.
4%
20%
56%
20%
AGE DISTRIBUTION
31-40
41-50
51-60
>60
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  Table 2- Gender distribution according to age
Age distribution Male Female Total
31-40 3 - 3
41-50 15 - 15
51-60 27 15 42
>60 3 12 15
Total 48 27 75
         
        
     Comment – In our study the mean age of females was around 60.88 
with a standard deviation of  4.81. In the 4th and 5th decade there were no 
females in our study. This is probably because women in their child-
bearing years are protected from the ill-effects of atherosclerosis by the 
protective effects of estrogen.
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Table 3 :Gender distribution among study population
Gender Euthyroid
CONTROLS
Sick euthyroid Hypothyroid Total
Male 34 11 3 48(64%)
Female 18 4 5 27(36%)
Total 52(69.33%) 15(20%) 8(10.66%) 75(100)%
Comment : Myocardial infarction is more common in males ( 64%) 
compared to females (36 %).
However hypothyroidism is more common among females in the general 
population and this is seen among MI patients in our study also (females
62.5%, males-37.5% )
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Table 4- Distribution of Patients with History of 
and Hypertension
Euthyroid
Diabetes 11
Hypertension 17
Total 28
Comment- Diabetes and hypertension are major risk factors for STEMI. 
Out of the 75 patients, 40 patients had either DM,SHT or both. Out of  the 
23 patients with thyroid dysfunction, 12 had DM,SHT or both.
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Diabetes Mellitus 
Sick euthyroid Hypothyroid
4 1
5 2
9 3
Hypertension
17
5
1
2
Total
16
24
40
Euthyroid
Sick euthyroid
Hypothyroid
Table 5 -Distribution of Smokers among the Study population
Euthyroid
Smokers 33
Non 
smokers
19
Total 52
Comment : Smoking is one of the most important modifiable risk factors 
for CAD. The prevalence of smoking in our study was 61.33 %.In our 
study all the females were non
were non-smokers. 
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Table-6 Mortality rates amo
Outcome Euthyroid 
(control)
Death 1
Discharge 51
Total 52
Comment : The total number of deaths was 8.Out of this, the maximum 
deaths occurred in the sick euthyroid
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ng the study population
Sick euthyroid Hypothyroid
6 1
9 7
15 8
group-6 
SICK 
EUTHYROID
HYPOTHYROID
6
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7
Total
8
67
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DISCHARGE
DEATH
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Table 7 - Mortality rates among patients with normal thyroid 
function and sick euthyroid state (hypothyroid patients excluded 
from comparison)
Outcome Death Discharge Total
Euthyroid(control) 1 51 52
Sick Euthyroid 6 9 15
Total 7 60 67
Chi square value- 14.200. Degree of freedom-1.  
P value 0.0002.This is statistically significant.
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Table 8- Comparison of mortality rates between hypothyroid group 
and control group
Outcome Death Discharge Total
Euthyroid 
(control)
1 51 52
Hypothyroid 1 7 8
Total 2 58 60
Comment : Chi squared equals 0.244 .Degree of freedom is 1.
                   The P value equals 0.6215.It is not statistically significant.
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Table 9- Incidence of cardiac failure among patients with normal 
thyroid function and sick euthyroid state
Cardiac Failure No cardiac 
failure
Total
Euthyroid 
(control)
3 49 52
Sick Euthyroid 10 5 15
Total 13 54 67
Comment : The Chi square value is 23.851. Degree of freedom is 1
                   p value is <0.0001. This is statistically significant.
Sick euthyroid state is associated with an increased incidence of cardiac
failure.
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Table 10- Incidence of arrhythmias among patients with normal 
thyroid function and the sick euthyroid state
Arrhythmia No arrhythmias Total
Euthyroid  
(control)
1 51 52
Sick euthyroid 5 10 15
Total 6 61 67
Comment :  The Chi square value is 10.498. Degree of freedom is 1
p value is 0.012.This is statistically significant.
Sick euthyroid state shows a positive association with occurrence of 
ventricular arrhythmias
98
Table 11- Incidence of MACE among patients with normal thyroid 
function and the sick euthyroid state
MACE No MACE Total
Euthyroid (control) 5 47 52
Sick Euthyroid 12 3 15
Total 17 50 67
Comment :
The Chi square value is 26.855. Degree of freedom is 1
p value is <0.0001. This is statistically significant.
COMMENT : The total number 
which 12 belonged to the sick euthyroid group. The incidence of MACE 
is higher in the sick euthyroid group and this is also found to be 
statistically significant.
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Table 12 : Univariate Analysis of all the parameters studied among the 
normal thyroid profile group and the sick euthyroid group
PARAMETER NORMAL 
THYROID 
PROFILE
SICK 
EUTHYROID 
STATE
P VALUE
Male gender 34 11 0.7906
Presence of 
DM/HT
15 9 0.0560
Smokers 33 10 0.8196
Cardiac failure 3 10 <0.0001
Ventricular 
arrhythmias
1 5 0.012
Death 1 6 0.0002
Comment : When a univariate analysis was done with all the parameters 
included in the study, a significant p value was found only with the 
incidence of Cardiac failure, ventricular arrhythmias and death in the SES 
group compared to the normal thyroid profile group.
101
DISCUSSION
             Myocardial Infarction is one of the most common and dreaded 
complications of atherosclerosis in the world today. There are numerous 
scoring systems used to predict prognosis when a patient gets admitted 
with Myocardial Infarction. The thyroid hormones affect the 
cardiovascular system in multiple ways and at multiple levels6. In this 
study we analyzed the thyroid profile of 75 patients admitted with 
features of ST-elevation myocardial infarction. 
             Our main aim was to study the thyroid profile in these patients 
and evaluate if the thyroid profile can be used as a predictor of mortality 
and as a prognostic indicator in them.
            Among the 75 patients, 15 were found to have a low fT3 with a 
normal TSH and fT4- a profile characteristic of the sick euthyroid state.8 
patients were found to have elevated TSH with normal or low fT3 and 
fT4 values- a picture characteristic of subclinical/overt hypothyroidism.
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AGE AND GENDER
             Out of the 75 patients admitted with STEMI, 42 patients were in 
the age group 51-60years.This corresponds to 56% of the study 
population. The mean age of the males in the study was 52.25 and 
females was 60.88.
            Among the 75 patients, 27 patients were female and 48 were 
male. Myocardial infarction was more common in males. This was seen 
in both the normal thyroid profile group and the sick euthyroid groups. 
However in the hypothyroid group, only 3 of the 8 patients were males. 
This may be indicative of the fact that hypothyroidism is more prevalent 
among women than men in the general population26.
          The incidence of MI also increases with age as seen by 56% of the 
patients falling in the 51-60 years age group. Increasing age and male 
gender remain important non-modifiable risk factors for CAD.
          The mean age was higher among women (60.88 years) in our 
study. CAD is more common in the postmenopausal group in women. 
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This is because of the protective effect offered by estrogen in the child 
bearing years of a woman’s life26.
Other risk factors
            In our study, the total number of patients with a history of 
Diabetes Mellitus was 16 and those with a history of hypertension was 
24.This indicates that 53.33% of the patients in our study had at least one 
modifiable risk factor.
             Among the patients with a normal thyroid function, 28 patients 
had DM or SHT (53.84%). Among the sick euthyroid patients, 9 patients 
had DM or SHT (60%). This is not statistically significant (p value-
0.8985).
SMOKING
            46 of the 75 patients had a history of smoking. This is 61.33% of 
the study population. All the women were non-smokers. Hence smoking 
remains the most important modifiable risk factor affecting the natural 
history of CAD.
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           Among the 3 groups, smoking was less prevalent in the 
hypothyroid group, probably because this group had more women. No
statistical difference was found between the prevalence of smoking in the 
normal thyroid profile group and the sick euthyroid group27,28.
INCIDENCE OF MACE
                  MACE or major adverse cardiac events refers to cardiac 
failure, ventricular arrhythmias and death. The total number of patients 
with MACE in our study was 17 (22.66%).Out of these, 12 patients 
belonged to the sick euthyroid group. Among the sick euthyroid group of 
15 patients, 12 had a major adverse cardiac event (80%). In the 
hypothyroid group, the incidence of MACE was 25%. In the control 
group with a normal thyroid profile, the incidence was 9.6%.
                     The incidence of MACE was found to be statistically 
significant in the sick euthyroid group with a p value of <0.0001 . This is 
in accordance with the results of the study “Sick euthyroid syndrome is 
associated with poor prognosis in patients with STEMI undergoing 
primary percutaneous intervention” published in the Cardiology journal 
where 472 patients with STEMI were studied. The incidence of in-
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hospital MACE was found to be significantly higher in the thyroid 
dysfunction group and the most common MACE seen was mortality1.
CARDIAC FAILURE AND VENTRICULAR ARRYTHMIAS
               15 patients out of the 75 study population developed cardiac 
failure. Out of these, 10 patients belonged to the sick euthyroid group 
(66.67%), 3 belonged to the normal thyroid profile group (20%) and 2 
belonged to the hypothyroid group (13.33%).
              The incidence of cardiac failure in the sick euthyroid group is 
statistically significant with a p value of <0.001. 
                Ventricular arrhythmias occurred in 7 people out of the 75.        
5 people belonged to the sick euthyroid group and among the normal 
thyroid profile group and the hypothyroid group, the number of patients 
with arrhythmia was 1 each.
               The incidence of ventricular arrhythmias in the sick euthyroid 
group is found to be statistically significant (71.48%)  with a p value of
0.012.
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          This is in accordance with the study by Kazim Serhan Ozcan, 
et al. “Sick euthyroid syndrome is associated with poor prognosis in 
patients with STEMI undergoing primary percutaneous intervention”1.
MORTALITY
           Out of 75 patients in the study, 8 patients died. 6 of these belonged 
to the sick euthyroid group ( 75%). One patient each from the other 2 
groups died.
            The mortality rate among the sick euthyroid group is 75% and 
this is statistically significant with a p value of 0.0002.
           This is in accordance to the study “Evaluation of Thyroid 
Dysfunction in Acute Coronary Syndrome” conducted by “Saurabh 
Potdal, Hetab Patel and Nivedita Mehta” in Baroda Medical College. In 
this study patients were divided into 2 groups- STEMI and 
NSTEMI/Unstable Angina. 21% patients were found to have a sick 
euthyroid syndrome on the day of admission. Mortality rates were found 
to be higher in the STEMI group who had presented with a sick euthyroid 
state 3.
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             This association was also seen in a study “Association between 
increased levels of reverse triiodothyronine and mortality after acute 
myocardial infarction”  by Leif Friberg et al. Here elevated rT3 levels 
were found to be associated with higher mortality levels.rT3 is  another 
marker of the sick euthyroid state6.
             In a study done in Brazil, “ Thyroid Hormone Profile in Acute 
Coronary Syndromes” Rodrigo Caetano Pimentel, Gilberto Perez 
Cardoso, Claudia Caminha Escosteguy et al studied 70 patients with 
ACS divided into 2 groups- those with STEMI and those with 
NSTEMI/Unstable angina. Thyroid hormones were measured on the day 
of admission and sick euthyroid state was defined as a normal TSH, 
Total/free T4 with an elevated reverse T3 and a low total/free T3. The 
group of patients with STEMI were found to have an earlier onset of 
thyroid hormone dysfunction and a higher mean reverse T3 and lower 
mean free/total T3 levels. The rates of mortality were also found to be 
higher in the STEMI group with sick euthyroid state15.
                  The exact mechanism by which a sick euthyroid state leads to 
an increased incidence of MACE and increased mortality is not clear54. 
So far, studies have not shown an improvement in the prognosis 
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following treatment of the sick euthyroid state with levothyroxine.  
Irrespective of the mechanism involved, patients with a sick euthyroid 
state at the time of an acute myocardial infarction are at an increased risk 
of arrhythmias, cardiac failure and death and hence will benefit from 
longer intensive care and close monitoring during follow-up.
LIMITATIONS OF THE STUDY :
 The study population was small. 
 Thyroid profile was done only once. At the time of discharge, a 
repeat thyroid profile may show the normalisation of the fT3 levels 
if the patient has recovered from the sick euthyroid state.
 Follow up of the patients was done only till discharge. Long term 
follow up needs to be done to see if the sick euthyroid state has any 
effect on long term recovery.
110
SUMMARY
The cardiovascular system and the thyroid hormones are linked at 
multiple levels  and in multiple ways. This study was conducted in 75 
patients presenting with ST elevation Myocardial Infarction. Thyroid 
profile was done in all of them.
 The number of males in the study was 48  (64%) and their mean 
age was 52.25.
 The number of females was 27 (36%) and their mean age was
60.88.
 The total number of patients who were smokers is 46 (61.33%).
 Diabetics constituted 21.33%  (16 patients)of the population and 
hypertension was seen in 24 patients (32%)
 The number of patients with a normal thyroid profile at the time of 
presentation was 52 and 18 of them were females.
 The number of patients with sick euthyroid state at the time of 
STEMI was 15 and 4 of them were females.
 The number of hypothyroid patients in the study was 8 and 5 of 
them were females.
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 The number of patients who had atleast one major adverse cardiac 
events (MACE) is 19. Out of this, 12 patients belonged to the sick 
euthyroid group.
 15 patients developed cardiac failure, 10 of them belonged to the 
sick euthyoid group. Ventricular arrhythmias were seen in 7 
patients, with 5 of them in the sick euthyroid category.
 The number of deaths was 8 and 6 of the patients were part of the 
sick euthyroid group.
                The sick euthyoid state was seen in 20% of  the study 
population and it was associated with an increased rate of MACE. There 
was a statistically significant association between the presence of the sick 
euthyroid state and the occurrence of cardiac failure, ventricular 
arrhythmias and death.
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CONCLUSION
The sick euthyoid state is seen when a patient suffers from any serious 
illness. This study was done to :
 Look for any changes in the thyroid profile when a patient 
presents with an acute ST elevation myocardial infarction.
 Evaluate if the presence of any such changes has an effect on the 
course of the illness.
               When a patient presents with an acute myocardial infarction, 
some of them develop a sick euthyroid state. This may be part of the 
body’s compensatory mechanism to try and reduce the metabolic 
demand of the heart. However it happens to be counter-productive.             
The sick euthyroid state shows a positive association with the occurrence
of MACE.
                 STEMI patients who present with a sick euthyroid state have a 
worse prognosis and have an increased risk of developing failure, 
arrhythmias and death. They may need a longer duration of intensive care 
and close monitoring during follow-up.
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PROFORMA
Name :                                                                                     Case No. :     
Age & Sex :
IP no. :
Occupation :
Address :
Date of Admission :
Date of Discharge :
Chief Complaints :
Chest pain- onset, duration, nature of pain
Breathlessness, palpitations, syncope
Past History : History of Diabetes ,Hypertension, CAD
                        History of Thyroid disorder,CKD, CLD
                        History of  Drug intake
Personal History : Smoker /Alcoholic
Clinical Examination :
General examination
Vitals : PR-    
             BP-       
Examination of the Cardiovascular system-               
Other systems :
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ECG changes :
DIAGNOSIS :
Serum TSH -
Serum fT3 -
Serum fT4 -
Course of patient in hospital :
Treatment given –Anticoagulation alone /Thrombolysis/ PCI/Stenting
Complications : Congestive cardiac failure
                           Ventricular arrhythmias
                           Cardiac arrest    
Duration of stay in ICU :
Outcome : Recovered
                  Expired inspite of treatment
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S.No. Age Gender DM SHT Thrombolysis Smoking fT3 fT4 TSH hypothyroid MACE SES ccf Arrhythmia outcome
1 52 m n n y y 2.19 0.66 13.13 y N n n n dis
2 60 f y y n n 2.36 1.14 0.91 n N n n n dis
3 60 f n n y n 2.32 1.29 11.44 y N n n n dis
4 65 m n n y y 2.32 0.99 6.1 y N n n n dis
5 62 f n y y n 2.24 1.16 7.38 y N n n n dis
6 46 m n n n y 2.05 1.16 1.28 n Y y N y dis
7 42 m y y y y 2.04 1.1 0.32 n Y y y n death
8 55 f y y n n 2.58 1.27 2.04 n Y n Y n death
9 80 f n n n n 2.32 0.97 2.98 n N n n n dis
10 50 m n n y n 2.06 0.86 1.15 n Y y y n dis
11 57 m n y y y 2.59 0.91 3.43 n N n n n dis
12 66 f y y y n 2.36 1.07 1.29 n N n n n dis
13 51 m n n n y 3.12 1.38 2.08 n Y n n y dis
14 42 m n y n y 2.4 1.35 0.31 n N n n n dis
15 59 m n n n n 2.32 0.94 4.57 n N n n n dis
16 33 m n n y y 2.2 1.11 2.06 n N y N n dis
17 56 m n n y y 1.54 0.73 1.65 n Y y y n death
18 65 m n n n y 2.42 1.19 1.04 n N n n n dis
19 55 f y y n n 2.32 1.05 0.45 n N n n n dis
20 40 m n n n y 2.59 1.3 0.58 n N n n n dis
21 56 m n n y y 2.32 0.99 1.8 n N n n n dis
22 50 m n n y y 2.88 1.22 3.08 n N n n n dis
23 56 m n n y n 2.34 1.41 0.63 n N n n n dis
24 50 m n n n y 3.49 1.14 1.98 n N n n n dis
25 60 f n n n n 2.3 1.03 3.25 n N n n n dis
26 53 m n n y y 2.66 1.04 0.84 n N n n n dis
27 58 m y y y y 2.4 1.23 2.45 n N n n n dis
28 60 m n n y y 3.12 1.66 4.56 n N n n n dis
29 61 f y y n n 3.25 1.21 4.12 n N n n n dis
30 62 m n n y y 2.5 1.43 4.6 n N n n n dis
31 54 m n n y y 2.16 1.45 3.12 n Y y y n dis
32 55 m n n y y 2.7 1.54 4.19 n N n n n dis
33 59 f y y n n 2.34 1.33 8.24 y N n n n dis
34 52 m n n y y 2.88 1.31 4.9 n N n n n dis
35 49 m n n y y 2.19 1.74 3.64 n N n n n dis
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36 47 m n n y y 2.08 1.55 2.55 n Y y y n death
37 48 m y y n n 2.78 1.29 4.26 n N n n n dis
38 63 f n n y n 2.36 1.22 3.89 n N n n n dis
39 62 f n n y n 2.9 1.6 2.15 n N n n n dis
40 50 m y y n y 2.45 1.39 3.48 n N n n n dis
41 51 m y y n y 2 0.92 1.24 n Y y y y dis
42 60 f n n y n 2.87 1.28 4.36 n Y n y n dis
43 54 m n n y y 2.56 1.21 10.26 y N n n n dis
44 52 m n y n y 3.65 1.33 4.25 n N n n n dis
45 58 f n n n n 3.58 1.42 3.64 n N n n n dis
46 55 f n n y n 2.1 1.12 1.69 n N y N n dis
47 60 f n n n n 2.7 1.78 4.56 n N n n n dis
48 60 m y y n y 2.9 1.2 4.7 n N n n n dis
49 61 f n n n n 2.36 1.11 12.54 y Y n n y death
50 56 m n y y y 2.48 1.26 3.45 n Y N Y n dis
51 64 f n n n n 2.47 1.13 4.79 n N n n n dis
52 65 f y y y n 1.98 1.24 2.33 n N y n n dis
53 59 f n n n n 3.69 1.12 2.45 n N n n n dis
54 55 m n n n y 3.78 0.9 5.12 n N n n n dis
55 48 m n n y y 3.55 1.55 4.19 n N n n n dis
56 60 f n y n n 2.1 1.05 2.4 n Y y y y death
57 62 f y y n n 2.88 1.36 3.48 n N n n n dis
58 52 m n n y y 2.48 1.09 3.47 n N n n n dis
59 60 m n n n y 2.17 1.26 3.22 n Y y y y dis
60 59 m y y y y 4.19 0.89 2.69 n N n n n dis
61 63 f n n n n 3.66 1.23 2.47 n N n n n dis
62 59 f n n n n 2.45 1.1 10.36 y Y n y n dis
63 53 m n n y y 2.78 1.48 3.78 n N n n n dis
64 49 m n n y y 2.11 1.45 4.09 n Y y y n dis
65 54 m n n y y 3.15 1.22 3.15 n N n n n dis
66 55 f n y n n 2.68 1.14 3.79 n N n n n dis
67 58 f n n n n 4 0.9 2.14 n N n n n dis
68 50 m n n y y 2.19 1.88 3.68 n Y y n n death
69 52 m n n n y 3.89 1.34 4.12 n N n n n dis
70 38 m n y y y 3.47 1.26 3.64 n N n n n dis
71 49 m n n n y 2.79 1.44 2.78 n Y n y n dis
72 55 m n n n y 2.9 1.08 4.19 n N n n n dis
73 53 m n n y n 3.18 1.78 3.47 n N n n n dis
74 62 f y y y n 2.06 1.33 2.5 n y y y y death
75 50 m n n y y 3.77 1.07 3.25 n N n n n dis
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Key to Master chart
DM- Diabetes Mellitus
HT- Hypertension
M- Male
F-Female
Y-Yes
N-No
SES-sick euthyroid state
Ccf-cardiac failure
Dis-discharge
fT3-Free T3
fT4- Free T4
MACE- Major adverse cardiac event
